Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimum Treatment for Drug-Resistant Hypertension
NCT02369081Phase 4Unknown
- Sponsor
- University of Cambridge
- Start
- May 2009
- Primary completion
- Jul 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of spironolactone, bisoprolol and doxazosin in hypertension (HTN) (4 arms), sponsored by University of Cambridge. Primary endpoint: Home blood pressure measurement at 48 weeks. Status: unknown.
02
Drugs
spironolactonebisoprololdoxazosin
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02369081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02369081.